Terns plans to move to a Phase 2 trial for its TERN-601 small-molecule GLP-1 receptor agonist and will submit the latest data to a coming scientific conference.
Add A Comment
Terns Pharmaceuticals’ stock soars 26% after biotech posts positive results in trial of weight-loss drug in pill form
By